Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

January 1, 2025

Conditions
Thyroid Cancer
Interventions
DRUG

Ondansetron 8mg

Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter

DRUG

Aprepitant 125 mg

Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)

Trial Locations (1)

Unknown

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER

NCT06697782 - Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer | Biotech Hunter | Biotech Hunter